| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
|
|
|
||||||||||
|
||||||||||||
The British Journal of Psychiatry 173: 236-241 (1998)
© 1998 The Royal College of Psychiatrists
MJ Travis, GF Busatto, LS Pilowsky, R Mulligan, PD Acton, S Gacinovic, J Mertens, D Terriere, DC Costa, PJ Ell and RW Kerwin
Department of Psychological Medicine, Institute of Psychiatry, London. sphamjt@iop.bpmf.ac.uk
BACKGROUND: 5-HT2A receptor antagonism may be crucial to the action of atypical antipsychotics. Previous work has related 5-HT2A receptor blockade to clinical efficacy and protection from extrapyramidal side- effects. METHOD: We developed a SPET imaging protocol for assessing 5- HT2A receptor binding using the selective ligand 123I-5-I-R91150. Six healthy volunteers, five clozapine- and five risperidone-treated subjects with DSM-IV schizophrenia were studied. Multi-slice SPET was performed on each subject. RESULTS: Cortex:cerebellum ratios were significantly lower in both clozapine- and risperidone-treated subjects compared with the healthy volunteers in all cortical regions. There was no difference in occupancy between the two drug-treated groups. No correlation was found between the percentage change in the Global Assessment Scale (GAS) and 5-HT2A receptor binding indices in the drug- treated groups. CONCLUSIONS: Clozapine and risperidone potently block 5- HT2A receptors in vivo. The lack of relationship between receptor binding indices and change in GAS suggests that 5-HT2A receptor blockade may be unrelated to clinical improvement. Future studies will substantiate this finding by studying 5-HT2A receptor binding in large groups of patients treated with both typical and novel atypical antipsychotics.
This article has been cited by other articles:
|
|
 |
|
  A. M. Catafau, M. Danus, S. Bullich, J. Llop, J. Perich, V. J. Cunningham, P. Plaza, M. M. Penengo, J. L.H. Eersels, L. Squassante, et al. Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 1--Pseudoequilibrium Interval and Quantification Methods J. Nucl. Med., June 1, 2006; 47(6): 919 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Catafau, M. Danus, S. Bullich, G. Nucci, J. Llop, S. Abanades, V. J. Cunningham, J. L.H. Eersels, J. Pavia, and M. Farre Characterization of the SPECT 5-HT2A Receptor Ligand 123I-R91150 in Healthy Volunteers: Part 2--Ketanserin Displacement J. Nucl. Med., June 1, 2006; 47(6): 929 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Bressan, H. M. Jones, and L. S. Pilowsky Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity J Psychopharmacol, March 1, 2004; 18(1): 124 - 127. [Abstract] [PDF]
|
|
|
|
|
|
K. Audenaert, K. Van Laere, F. Dumont, M. Vervaet, I. Goethals, G. Slegers, J. Mertens, C. van Heeringen, and R. A. Dierckx Decreased 5-HT2a Receptor Binding in Patients with Anorexia Nervosa J. Nucl. Med., February 1, 2003; 44(2): 163 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. JONES and L. S. PILOWSKY Dopamine and antipsychotic drug action revisited The British Journal of Psychiatry, October 1, 2002; 181(4): 271 - 275. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Reneman, J. B. A. Habraken, C. B. L. Majoie, J. Booij, and G. J. den Heeten MDMA ("Ecstasy") and Its Association with Cerebrovascular Accidents: Preliminary Findings AJNR Am. J. Neuroradiol., June 1, 2000; 21(6): 1001 - 1007. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |
